Tuberculosis - the opportunity in our lifetime Dr. Lucica Ditiu | Executive Secretary | Stop TB Partnership 09.April.2013 | Brussels, Belgium.

Slides:



Advertisements
Similar presentations
Stop TB Strategy Planning Frameworks Mukund Uplekar TB Strategy, Operations and Health Systems, Stop TB Department, WHO.
Advertisements

New approaches in TB diagnosis and treatment Prof. M.A. Tageldin.
Pharmaceuticals and Global Health Inequalities and Innovation in the 21 st Century.
Dr. E. Anne Peterson, MD, MPH Assistant Administrator, Bureau for Global Health, USAID Sustainable Investment and Donor Coordination Stop TB Partners Forum.
TB and HIV: Tightly Linked… and Why We Should Care.
ARIAtlas.org. Global Impact TB causes nearly two million deaths a year, making it the world’s seventh most common cause of mortality. More than two billion.
Overview of current case and treatment outcome definitions Malgosia Grzemska TB Operations and Coordination Stop TB Department Consultation Impact of WHO-endorsed.
Christine Lubinski Vice President for Global Health Infectious Diseases Society of America April 17, 2009 Germs Go Global Tuberculosis and HIV/TB Co-Infection.
Tuberculosis Drugs Spreadsheet Documentation. General Information Link to spreadsheet: c?key=0AuIkrFbUTuZldHJPZGtUNV9CSVFraEQ0TWZ2.
TUBERCOLOSIS Agis Terzidis, Paediatrician Spyridon Gialamas, Medical Doctor SEMINAR ON TROPICAL AND TRAVEL MEDICINE AT TTCIH IFAKARA 25 JUNE 2009.
Technical Advisory Group meeting, WHO/WPRO
Global Plan to Stop TB Stop TB Partnership
Tuberculosis quick facts Illustrated through drawings from children across the Region Philippines.
Status of Revised National Tuberculosis Control Program (RNTCP) in India Dr Jitendra.
1 Global and Regional Tuberculosis (TB) update ACSM workshop, Amman, Jordan April 13-17, 2008 Dr. Sevil Huseynova.
22 March 2012 Europe and ACP together against tuberculosis European Parliament, Rue Wiertz 60 BRUSSELS Charles S Mgone EDCTP Executive Director.
Innovation in TB control: what’s in it for the field? Peter C.F.M. Gondrie, MD, MPH Executive Director
Impact evaluation Evaluate new tools Translate new knowledge into policy and implementation Knowledge gap Program implementation.
MDR-TB: a fight we cannot afford to lose! Alexander Golubkov, MD, MPH Senior TB Technical Advisor.
PUTTING AN END TO TB WHERE ARE THE OPPORTUNITIES AND WHAT ARE THE CHALLENGES? STRATEGY MEETING ON RESOURCE MOBILIZATION FOR THE GLOBAL FUND TO FIGHT AIDS,
THE FIGHT TO STOP TB WHAT ARE WE FIGHTING? TUBERCULOSIS: THE WORLD’S NO. 1 KILLER AMONG CURABLE, INFECTIOUS DISEASES But there is hope PEOPLE WHO HAVE.
EMERGING INFECTIOUS DISEASES: A CONTINUOUS CHALLENGE FOR EUROPE STOA-AVIESAN WORKSHOP JUNE 19TH 2012; EUROPEAN PARLIAMENT; BRUXELLES A sustainable agenda.
Bi-State TB Elimination April 10, 2014 Anna Frye Michelle Goodyear Tuberculosis: Recent Trends and Relevant Research.
Combat HIV-AIDS, malaria & other diseases Goal 6..
Mongolia Progress Report Dr. D. Otgontsetseg, Head of recording and reporting unit, TB surveillance and research department, NCCD The ninth Technical Advisory.
“World TB day and TB in Mongolia”
DEPARTMENT OF HEALTH DOTS Program for TB (Tuberculosis Directly Observed Short-course)
Tuberculosis Research of INA-RESPOND on Drug-resistant
TASK FORCE ON RETOOLING STOP TB PARTNERSHIP Cape Town November 2007.
WHO Expert Working Group on R&D Financing Stop TB New Tools Working Groups Marcos Espinal Executive Secretary.
The Research and Development Goals of the Global Plan to Stop TB Marcos Espinal Executive Secretary.
World TB Day 2000 Forging New Partnerships to Stop TB Produced by the [ Stop TB Initiative ] Coordinating Team: WHO.
TB PUBLIC-PRIVATE MIX DOTS Dr. Team Bakkhim Deputy Director CENAT Intercontinental Hotel 7 th November, 2012 NATIONAL FORUM ON PUBLIC-PRIVATE PARTNERSHIP.
Session 11: MDR & XDR-TB: How Can Business Help Stem the Tide?
World Health Assembly 63 Geneva, Suisse May 2010 WORLD HEALTH EDITORS NETWORK Tracking Global Health News: building health literacy Multi-Drug Resistant.
African Business Leaders on Health: GBC Conference on TB, HIV-TB Co-infection & Global Fund Partnership Johannesburg, October 11, 2010 The state of Global.
Missed opportunities to diagnose TB and HIV Co-infection in HIV workplace program Dr Fred Mugyenyi Asiimwe Medical Director, ALAFA.
Update of the Global Plan to Stop TB TB/HIV Working Group Meeting Geneva, November 2009 Christian Lienhardt.
End TB Strategy HCW with cough since January. Seen at government clinic thrice with no sputum/CXR. Diagnosed TB in May only.
Universal access to TB care what is the challenge, what policy, what is being implemented Cancun 3 December 2009 Léopold BLANC and TBS team TBS/STB/WHO.
INAT and Research Christian Lienhardt Stop TB Partnership Geneva First Meeting of the Core Group of the Subgroup on Introducing New Tools and Approaches.
1 [INSERT SPEAKER NAME DATE & LOCATION HERE] Ethics of Tuberculosis Prevention, Care and Control MODULE 2: BACKGROUND ON TUBERCULOSIS Insert country/ministry.
Proposed Post-2015 Global Tuberculosis Strategy and Targets Dr Mario Raviglione Director, Global TB Programme World Health Organization, Geneva, Switzerland.
Health Organization The Challenges Facing Tuberculosis Control Blantyre Hospital, Malawi: TB Division, 3 patients per bed.
Tuberculosis is a global public health issue. The Role of the International Agencies Introduction TB which stands for Tuberculosis is a rather infectious.
Philippe Duneton11 February 2009 Deputy Executive Secretary 5th Consultative Stakeholder Meeting UN Prequalification of Diagnostics, Medicines & Vaccines.
Meeting of the Working Group on TB Drug Development Why you need to be engaged? Marcos Espinal Executive Secretary Stop TB Partnership 29 October 2004.
Diagnostics - More than 100 years old Drugs – Last drug 40 years old Vaccine – Nearly 90 years old Lucica Ditiu Executive Secretary, Stop TB Partnership.
HIV TESTING AND EXPANSION OF ART FOR TB PATIENTS, BOTTLE NECKS CHALLENGES AND ENABLERS FOR SCALE UP IN KENYA DR. JOSEPH SITIENEI, OGW NTP MANAGER - KENYA.
PEPFAR The Global Fund and PEPFAR: Strategic Collaboration for Greater Impact Mark Edington, Director, Grants Management, Global Fund Julia Martin, Chief.
Dr Ral Antic Chair Scientific Committee IUATLD-APR Australia Pre-Conference Workshop 1 National TB Control Program Summary & Remarks.
Global Fund Grant Proposal Round 11: Tuberculosis Nathan Furukawa Gabriella Boyle Rebekah Miner Paa Kobina Forson Xiaoxue Huang Hunter Pugh Gap Analysis.
THE GLOBAL FUND SUSTAINING THE GAINS AND IMPACT Uganda November 2013.
Tuberculosis demand forecast Brussels, 10 April 2013 Dr Mario Raviglione Director, Stop TB Department World Health Organization, Geneva, Switzerland.
TB-HIV: What are we seeing in the communities? Mayowa Joel Treatment Action Movement (TAM), Nigeria.
TB AND HIV: “THE STRATEGIC VISION FOR THE COUNTRY” Dr Lindiwe Mvusi 18 May 2012 MMPA Congress 2012.
TB: Can we end it as AIDS in the future? Presentation for discussion RIHES December 9, 2015.
Outline The Global Fund Strategy emphasizes the Key Populations
Data for Action on TB Key, Vulnerable and Underserved Populations
financial requirements
Tailored Review Proposal for Tuberculosis
Incorporating transition considerations into the new Global Fund funding cycle Mauro Guarinieri Senior Technical Adviser, Community Responses and Drug.
Progress in Implementing collaborative TB/HIV activities
Pre-conference Meeting Report
Committee Task Statement (1)
22nd International AIDS Conference Amsterdam, 24 July 2018
Funding gaps to realize the Global Plan to End TB
Issues Workshop Year of Action for Ending Tuberculosis
The STOP TB Strategy – 2009 VISION: A TB-free world
A Time of Commitments and Actions to accelerate action to End TB
Presentation transcript:

tuberculosis - the opportunity in our lifetime Dr. Lucica Ditiu | Executive Secretary | Stop TB Partnership 09.April.2013 | Brussels, Belgium

the achieve ments GF funding provided TB treat to 9.7 mil people Contributed to increase of the case detection from 43% to 65% and treatment success from 67% to 87% in the 22 high burden countries

the achieve ments

Belgium Global 8 / 100k / 100k year TB incidence the burden

Population of Brussels 1.1 MILLION People who died of TB in MILLION the burden

1.4 MILLION People who died of TB in 2011 the burden

1.4 MILLION 9 MILLION estimated TB cases 6 MILLION cases diagnosed and treated MDR-TB 570,000 estimated cases that go undiagnosed & untreated the burden 59,000 MDR-TB cases diagnosed and treated

the lessons learned lives saved due to TB & HIV integration ( ) 1.5 MILLION 25 fold increase cases detected & treated due to prioritized interventions in vulnerable populations 25x doubled detection & treatment through engagement with TB communities

Cost effective TB interventions are the 4 th most cost effective among interventions to control disease (Copenhagen Consensus 2012) Cost per DALY gained varies between US$ for first line treatment and US$ for second line treatment Costs are being driven down: diagnostics and second line drugs New tools Gene Xpert: new rapid diagnosis for TB and Rif resistance rolled out (1,000 machine worldwide) First new anti-TB drug in 50 years New drug regimens for shorter treatment duration and fewer pills in clinical trials 12 vaccine candidates in the pipeline Strategic investment guidance Sustainable outlook with strong co-investment from countries Potential of mobilizing up to 60% of financial needs from domestic resources Opportunity to leverage domestic commitments the potential & tools

with the tools and expertise we have today we must accelerate our efforts and investments for tomorrow

1.4 MILLION cases diagnosed and treated MDR-TB 570,000 estimated cases that go undiagnosed & untreated the vision 59,000 MDR-TB cases diagnosed and treated cases diagnosed and treated 630,000 diagnosed and treated 9 MILLION estimated TB cases with

Potential lives saved with treatment TB TB/HIV MDR-TB the impact potential lives saved with full funding through MILLION

9 MILLION estimated TB cases with 9 MILLION cases diagnosed and treated the vision MDR-TB 630,000 diagnosed and treated a world free of TB

thank you